About AB-Biotics
AB-Biotics is a company based in Barcelona (Spain) founded in 2004 by Miquel Angel Bonachera was acquired by Kaneka in September 2019. AB-Biotics offers products and services including Probiotic Strains, Probiotic Formulas, and Market-ready Probiotic Products. AB-Biotics operates in a competitive market with competitors including Denali Therapeutics, Novozymes, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
- Headquarter Barcelona, Spain
- Founders Miquel Angel Bonachera
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ab-Biotics, Sa
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AB-Biotics
AB-Biotics offers a comprehensive portfolio of products and services, including Probiotic Strains, Probiotic Formulas, and Market-ready Probiotic Products.
Unique strains with mechanisms of action for targeted health applications.
Scientifically-documented solutions for various therapeutic health needs.
Premium formulations adapted for functional food and pharmaceutical markets.
People of AB-Biotics
Unlock access to complete
Funding Insights of AB-Biotics
Investors in AB-Biotics
AB-Biotics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Almirall, European Union and Kaneka.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Inveready is recognized as a leading Spanish financial services firm.
|
Locked | Locked | Locked | |
|
Venture capital investment fund
|
Locked | Locked | Locked |
Investor details for AB-Biotics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AB-Biotics
Investment portfolio details for AB-Biotics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AB-Biotics
Detailed financials for AB-Biotics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ab-Biotics Comparisons
Peer comparison for AB-Biotics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AB-Biotics
AB-Biotics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Novozymes, Poseida Therapeutics, Castle Biosciences and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of AB-Biotics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ab-Biotics
Complete news archive for AB-Biotics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AB-Biotics
AB-Biotics was founded in 2004 and raised its 1st funding round 8 years after it was founded.
AB-Biotics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Miquel Angel Bonachera is the current CEO of AB-Biotics. They have also founded this company.
AB-Biotics was founded in 2004 in Barcelona, Spain, focusing on the biotechnology and pharmaceutical sectors. Probiotic drugs are developed primarily for dental disorders, with a portfolio of 21 products spanning categories such as cardiometabolic health, oral care, pediatrics, gastrointestinal health, gynecology, urology, dermatology, and immunology. Drugs for central nervous system disorders are also created. Nutraceuticals are provided for pharmaceutical and food industries, alongside services in genetic analyses for pharmacogenetic studies.
AB-Biotics's top competitors include Juno Therapeutics, Novozymes and Poseida Therapeutics.
AB-Biotics offers Probiotic Strains, Probiotic Formulas, and Market-ready Probiotic Products.
AB-Biotics has 6 investors. Key investors include Almirall, European Union, Kaneka, EIC Fund, and Inveready.